Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment elevation myocardial infarction (STEMI) patients following percutaneous coronary intervention (PCI) using point-of-care genetic testing for the CYP2C19\*2, \*17, and ABCB1 3435 C\>T alleles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260

Myocardial Infarction

TERMINATED PHASE2

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

NCT03435133

ST Elevation Myocardial Infarction

COMPLETED NA

Implementing Precision Medicine Approaches to Guide Anti-platelet Selection

NCT04090281

Acute Coronary Syndrome (ACS) STEMI - ST Elevation Myocardial Infarction (MI) NSTEMI - Non-ST Segment Elevation MI +1 more

UNKNOWN PHASE4

Adjunctive, Low-dose tPA in Primary PCI for STEMI

NCT03335839

Myocardial Infarction Percutaneous Coronary Intervention

COMPLETED PHASE3

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

NCT00976092

Myocardial Infarction

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dual anti-platelet therapy following percutaneous coronary intervention (PCI) for the treatment of STEMI has traditionally consisted of aspirin and clopidogrel. Despite this treatment approach, a substantial portion of patients experience recurrent adverse cardiovascular events including death, myocardial infarction, and stent thrombosis. This persistent vulnerability has been associated with inadequate platelet inhibition in response to clopidogrel administration, a phenomenon referred to as high on-treatment platelet reactivity. Although multiple variables have been implicated in altered clopidogrel response, mounting evidence has suggested a crucial role for common genetic variants including: CYP2C19\*2, \*17, and ABCB1 3435 C\>T alleles.

Presence of the CYP2C19\*2 allele has been associated with a 1.5- to 6-fold increased risk of cardiovascular death, myocardial infarction, and stent thrombosis following PCI in patients treated with clopidogrel. These findings, recently bolstered by 2 separate meta-analyses, led the American Food and Drug Administration to issue a boxed warning for clopidogrel stating that poor metabolizers may not receive the full benefit of the drug. The ABCB1 3435 TT genotype has also been linked with increased adverse cardiovascular events in individuals treated with clopidogrel following PCI for an acute coronary syndrome. In contrast, the CYP2C19\*17 gain-of-function allele appears to enhance the activity of clopidogrel and has been associated with reduced ischemic events but increased bleeding.

As a result of these findings, experts have begun to advocate for routine genotyping in the context of PCI. A personalized approach to dual anti-platelet therapy following PCI is feasible given the presence of treatment alternatives such as prasugrel that are capable of overcoming clopidogrel resistance. Selective administration of prasugrel to patients at increased risk of clopidogrel resistance has the potential to successfully minimize adverse ischemic events, while simultaneously minimizing associated bleeding events and health care costs. A prospective pharmacogenomic approach to anti-platelet therapy has been previously hampered by limited access and the time-delay associated with genetic testing. The development of point-of-care genetic testing for the CYP2C19\*2, \*17, and ABCB1 3435 C\>T alleles that requires minimal training to perform carries the potential to overcome these obstacles and may facilitate the incorporation of pharmacogenetic strategies into routine clinical practice.

Patients receiving PCI in the context of STEMI will undergo point-of-care genetic testing for the CYP2C19\*2, \*17, and ABCB1 3435 C\>T alleles. CYP2C19\*2 carriers and individuals homozygous for the ABCB1 3435 T allele will subsequently be randomized to prasugrel 10mg daily for 1 month or clopidogrel 150mg daily for 1 week followed by 75mg daily. The remaining individuals without an at-risk genotype will receive standard therapy with clopidogrel. At the end of the 1 month period, efficacy of the treatment strategies will be evaluated using VerifyNow platelet function testing. The effect of the CYP2C19\*17 allele will be prospectively evaluated during the treatment period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

STEMI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

At-Risk Genetics Arm: Prasugrel

Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.

Group Type EXPERIMENTAL

Point-of-Care Genetic Testing

Intervention Type GENETIC

Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Prasugrel

Intervention Type DRUG

Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.

At-Risk Genetics Arm: Clopidogrel

Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.

Group Type ACTIVE_COMPARATOR

Point-of-Care Genetic Testing

Intervention Type GENETIC

Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Low Risk Genetics Arm: Clopidogrel

Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.

Group Type ACTIVE_COMPARATOR

Point-of-Care Genetic Testing

Intervention Type GENETIC

Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Point-of-Care Genetic Testing

Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

Intervention Type GENETIC

Prasugrel

Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Spartan RX Effient

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and Females between the ages of 18 and 75 years
* STEMI patients treated with percutaneous coronary intervention
* Able to provide informed consent
* Able to comply with assigned treatment strategy and attend 1 month follow-up visit

Exclusion Criteria

* Receiving anti-platelet therapy other than aspirin and clopidogrel
* Receiving anti-coagulation with warfarin or dabigatran
* History of stroke or transient ischemic attack
* Platelet count \< 100 000/μL
* Known Bleeding Diathesis
* Hematocrit \<30% or \>52%
* Severe Liver Dysfunction
* Renal Insufficiency (Creatinine Clearance \< 30ml/min)
* Pregnant females

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No